Core Insights - Beijing Huaxi Rongxi Biotechnology Research Co., Ltd. and Peking University have successfully established the "Beijing Key Laboratory of Carbohydrate Manufacturing and Functional Applications," marking a significant achievement in the field of carbohydrate biology and synthetic biology [1][2] Group 1: Laboratory Establishment and Objectives - The newly approved laboratory is the first provincial-level key laboratory in Beijing focusing on carbohydrate science, filling a gap in the city's innovation ecosystem [2] - The laboratory aims to integrate resources to create a comprehensive innovation ecosystem covering "intelligent preparation - precise modification - functional application" [2] - Key research directions include carbohydrate biosynthesis, chemical synthesis, and functional applications, with a focus on developing health and pharmaceutical products based on carbohydrates [2][3] Group 2: Company’s Strategic Positioning - Huaxi Rongxi serves as the core technical support for the laboratory, focusing on high-value bioactive compound synthesis and has established five core technology platforms [3] - The company has been recognized as a national high-tech enterprise and has set up a postdoctoral research station, establishing itself as a leader in synthetic biology [3] Group 3: Strategic Foundation in Carbohydrate Biology - Carbohydrate biology is identified as a strategic foundation for Huaxi Biotechnology, expanding research from hyaluronic acid to a broader range of high-value carbohydrate materials [4] - The establishment of the laboratory is an extension of the company's carbohydrate biology strategy, enhancing its core competitiveness in the carbohydrate science field [4] Group 4: ECM Strategic Layout - The company has developed an innovative layout centered around extracellular matrix (ECM), which includes key components like hyaluronic acid and collagen, essential for cellular functions [5][6] - The laboratory's research aligns with the ECM strategy, aiming to enrich the ECM component library and understand the synergistic mechanisms between components [6] Group 5: Alignment with National Development Plans - The establishment of the laboratory aligns with China's "14th Five-Year Plan," emphasizing the importance of synthetic biology as a strategic emerging industry [7] - The company is committed to building a complete innovation system that meets the development requirements of the national strategy, focusing on green manufacturing and industry upgrades [7] - Huaxi Biotechnology's Tianjin base has become the largest synthetic biology pilot platform in China, significantly improving production efficiency and reducing energy consumption [7]

内容概况：弹性蛋白（Elastin）广泛存在于哺乳动物结缔组织，和胶原蛋白同为皮肤的重要组成部分， 胶原蛋白提供支撑作用，而弹性蛋白提供延展性与回弹性。2024年，中国弹性蛋白行业市场规模约为 6.27亿元，同比增长3.81%。其前体原弹性蛋白（tropoelastin）胞内合成后分泌到胞外，经酶催化交联 成为高度不溶的弹性蛋白网络，使弹性蛋白分子能够任意卷曲，具有高弹性。在应用领域，弹性蛋白通 常与胶原蛋白、透明质酸等成分复配作为护肤品成分以达到综合抗老化效果。其良好的生物相容性和弹 性能使其成为理想的生物医用材料，包括人工血管、创伤敷料、药物递送、伤口修复等多个方面。近年 来弹性蛋白主要用于补剂、化妆品、生物医药等领域，逐渐成为新的热点产品。 相关上市企业：丸美生物（603983） 二、行业产业链 相关企业：内蒙古伊利实业集团股份有限公司、山东得利斯食品股份有限公司、黑龙江宾西牛业有限公 司、温氏食品集团股份有限公司、牧原食品股份有限公司、新希望六和股份有限公司、北京大北农科技 集团股份有限公司、上海药明康德新药开发有限公司、深圳华大基因股份有限公司、苏州泓迅生物科技 股份有限公司、梅花生物科技集团股份有 ...

弹性蛋白（Elastin）是弹性纤维的核心成分，属于结缔组织中的硬蛋白，主要分布于皮肤、血管、肺、韧带、软骨等需要弹性的组织中。其核心功能是赋予 组织可逆的拉伸和回缩能力，如皮肤的紧致、血管的弹性扩张等。中国弹性蛋白行业以技术驱动为核心，2024年，中国弹性蛋白行业市场规模达6.27亿元， 同比增长3.81%。其生产分天然提取（牛颈韧带、猪主动脉等）和重组表达（大肠杆菌、酵母菌生物发酵）两类，重组技术通过合成生物学优化菌株，降低 生产成本并提升纯度。未来，合成生物学、绿色制造及多场景跨界融合将推动行业向低碳、高效、高附加值方向升级，政策规范与标准完善将进一步规范市 场发展。 基于此，依托智研咨询旗下弹性蛋白行业研究团队深厚的市场洞察力，并结合多年调研数据与一线实战需求，智研咨询推出《2026-2032年中国弹性蛋白行 业市场全景调研及发展潜力研判报告》。本报告立足弹性蛋白新视角，聚焦行业核心议题——变化趋势（怎么变）、用户需求（要什么）、投放选择（投向 哪）、运营方法（如何投）及实践案例（看一看），期待携手行业伙伴，共谋行业发展新格局、新机遇，推动弹性蛋白行业发展。 观点抢先知： 行业发展有利因素：合成生物学 ...